{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:reflocibart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:docaravimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
USAN:MAVEROPEPIMUT-S COMPONENT A16L [USAN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:demupitamab [INN]
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Source:
NCT02772822: Phase 3 Interventional Unknown status Diffuse Large B Cell Lymphoma
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:trastuzumab vedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00099580: Phase 2 Interventional Completed Congestive Heart Failure
(2005)
Source URL:
Class:
PROTEIN
AC-2592 (glucagon-like peptide 1, or GLP-1) was being in development by Amylin Pharmaceuticals for the treatment of severe congestive heart failure. AC-2592 is a glucagon like peptide 1 receptor agonist.
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
